Public Release:  Genetic study finds association between reduced vitamin D and multiple sclerosis risk

PLOS

Genetic findings support observational evidence that lower vitamin D levels are associated with increased risk of multiple sclerosis, according to a new research article by Brent Richards, from McGill University, Canada, and colleagues published this week in PLOS Medicine.

Multiple sclerosis is a debilitating autoimmune disease that affects the nerves in the brain and spinal cord. There is no known cure for multiple sclerosis and it usually presents between the ages of 20 and 40 years. While some observational evidence suggests there may be a link between lower vitamin D levels and multiple sclerosis risk, it is difficult to infer a causal relationship because individuals who develop multiple sclerosis in these studies might share another unknown characteristic that increases their risk of multiple sclerosis (this is known as confounding).

Using a genetic technique called Mendelian randomization to reduce the possibility of confounding the authors examined whether there was an association between genetically reduced vitamin D levels (measured by the level of 25-hydroxyvitamin D, the clinical determinant of vitamin D status) and susceptibility to multiple sclerosis among participants in the International Multiple Sclerosis Genetics Consortium study, which involves 14,498 people with multiple sclerosis and 24,091 healthy controls. The authors found that a genetic decrease in the natural-log-transformed vitamin D level by one standard deviation was associated with a 2-fold increased risk of multiple sclerosis.

While the Mendelian randomization approach used by the authors largely avoids the possibility of confounding or reverse causation, the reliability of these findings may be limited by some of the assumptions made by the researchers during their analysis.

Nevertheless the authors conclude, "genetically lowered vitamin D levels are strongly associated with increased susceptibility to multiple sclerosis. Whether vitamin D sufficiency can delay, or prevent, multiple sclerosis onset merits further investigation in long-term randomized controlled trials."

The authors also note, "ongoing randomized controlled trials are currently assessing vitamin D supplementation for the treatment and prevention of multiple sclerosis ... and may therefore provide needed insights into the role of vitamin D supplementation."

###

Research Article

Funding: JBR is funded by the Canadian Institute of Health Research, (MOP-119462) The Fonds de la Recherche en Santé Québec, the Lady Davis Institute, and the Jewish General Hospital. AL is supported by the Canadian Diabetes Association Postdoctoral Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: GT has accepted speaker's fees and consultancy fees from Servier Canada relating to the treatment of hypertension and has participated on an Advisory Board for ISIS Pharmaceuticals for the treatment of dyslipidemia. GT also receives research grants from the Canadian Institute of Health Research and the Heart and Stroke Foundation of Canada. GDS is a member of the Editorial Board of PLOS Medicine. None of these relationships relate to the content/topic of the manuscript under review at PLOS Medicine.

Citation: Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Leong A, et al. (2015) Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med 12(8): e1001866. doi:10.1371/journal.pmed.1001866

Author Affiliations:

Centre for Clinical Epidemiology, Department of Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Department of Medicine, McGill University, Montreal, Quebec, Canada
MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
Department of Oncology, McGill University, Montreal, Quebec, Canada
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
Department of Human Genetics, McGill University, Montreal, Quebec, Canada
Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
Preventive and Genomic Cardiology, McGill University Health Center, Montreal, QC
Department of Twin Research and Genetic Epidemiology, King's College London, United Kingdom

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001866

Contact:

Emmanuelle Paciullo
Relations médias et gouvernementales | Media and Government Relations
Communications et relations médias | Communications and Media Relations
CIUSSS du Centre-Ouest-de-l'Ile-de-Montreal
Integrated Health & Social Services University Network for West-Central Montreal
T: 514-340-8222 poste 4120
Téléavertisseur: 514-413-1289 (urgences médias)

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.